Literature DB >> 25827830

Circulating cell membrane microparticles transfer heme to endothelial cells and trigger vasoocclusions in sickle cell disease.

Stéphane M Camus1, João A De Moraes1, Philippe Bonnin2, Paul Abbyad3, Sylvain Le Jeune4, François Lionnet5, Laurent Loufrani6, Linda Grimaud6, Jean-Christophe Lambry3, Dominique Charue1, Laurent Kiger7, Jean-Marie Renard1, Claire Larroque8, Hervé Le Clésiau8, Alain Tedgui1, Patrick Bruneval1, Christina Barja-Fidalgo9, Antigoni Alexandrou3, Pierre-Louis Tharaux1, Chantal M Boulanger1, Olivier P Blanc-Brude1.   

Abstract

Intravascular hemolysis describes the relocalization of heme and hemoglobin (Hb) from erythrocytes to plasma. We investigated the concept that erythrocyte membrane microparticles (MPs) concentrate cell-free heme in human hemolytic diseases, and that heme-laden MPs have a physiopathological impact. Up to one-third of cell-free heme in plasma from 47 patients with sickle cell disease (SCD) was sequestered in circulating MPs. Erythrocyte vesiculation in vitro produced MPs loaded with heme. In silico analysis predicted that externalized phosphatidylserine (PS) in MPs may associate with and help retain heme at the cell surface. Immunohistology identified Hb-laden MPs adherent to capillary endothelium in kidney biopsies from hyperalbuminuric SCD patients. In addition, heme-laden erythrocyte MPs adhered and transferred heme to cultured endothelial cells, inducing oxidative stress and apoptosis. In transgenic SAD mice, infusion of heme-laden MPs triggered rapid vasoocclusions in kidneys and compromised microvascular dilation ex vivo. These vascular effects were largely blocked by heme-scavenging hemopexin and by the PS antagonist annexin-a5, in vitro and in vivo. Adversely remodeled MPs carrying heme may thus be a source of oxidant stress for the endothelium, linking hemolysis to vascular injury. This pathway might provide new targets for the therapeutic preservation of vascular function in SCD.
© 2015 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25827830      PMCID: PMC4490297          DOI: 10.1182/blood-2014-07-589283

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  53 in total

Review 1.  Pulmonary hypertension and nitric oxide depletion in sickle cell disease.

Authors:  H Franklin Bunn; David G Nathan; George J Dover; Robert P Hebbel; Orah S Platt; Wendell F Rosse; Russell E Ware
Journal:  Blood       Date:  2010-04-15       Impact factor: 22.113

2.  Programmed cell death in mature erythrocytes: a model for investigating death effector pathways operating in the absence of mitochondria.

Authors:  D Bratosin; J Estaquier; F Petit; D Arnoult; B Quatannens; J P Tissier; C Slomianny; C Sartiaux; C Alonso; J J Huart; J Montreuil; J C Ameisen
Journal:  Cell Death Differ       Date:  2001-12       Impact factor: 15.828

3.  Defect in microvascular adaptation to chronic changes in blood flow in mice lacking the gene encoding for dystrophin.

Authors:  Laurent Loufrani; Bernard I Levy; Daniel Henrion
Journal:  Circ Res       Date:  2002-12-13       Impact factor: 17.367

4.  Endothelial dysfunction in patients with sickle cell disease is related to selective impairment of shear stress-mediated vasodilation.

Authors:  L Belhassen; G Pelle; S Sediame; D Bachir; C Carville; C Bucherer; C Lacombe; F Galacteros; S Adnot
Journal:  Blood       Date:  2001-03-15       Impact factor: 22.113

5.  Oxidative stress and induction of heme oxygenase-1 in the kidney in sickle cell disease.

Authors:  K A Nath; J P Grande; J J Haggard; A J Croatt; Z S Katusic; A Solovey; R P Hebbel
Journal:  Am J Pathol       Date:  2001-03       Impact factor: 4.307

6.  Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease.

Authors:  Christopher D Reiter; Xunde Wang; Jose E Tanus-Santos; Neil Hogg; Richard O Cannon; Alan N Schechter; Mark T Gladwin
Journal:  Nat Med       Date:  2002-11-11       Impact factor: 53.440

7.  Fetal hemoglobin in sickle cell disease: relationship to erythrocyte phosphatidylserine exposure and coagulation activation.

Authors:  B N Setty; S Kulkarni; A K Rao; M J Stuart
Journal:  Blood       Date:  2000-08-01       Impact factor: 22.113

8.  Divergent nitric oxide bioavailability in men and women with sickle cell disease.

Authors:  Mark T Gladwin; Alan N Schechter; Frederick P Ognibene; Wynona A Coles; Christopher D Reiter; William H Schenke; Gyorgy Csako; Myron A Waclawiw; Julio A Panza; Richard O Cannon
Journal:  Circulation       Date:  2003-01-21       Impact factor: 29.690

9.  Selective protection of renal tubular epithelial cells by heme oxygenase (HO)-1 during stress-induced injury.

Authors:  Yonghong Yang; Kazuhide Ohta; Masaki Shimizu; Kayoko Morimoto; Chinami Goto; Akiko Nakai; Tomoko Toma; Yoshihito Kasahara; Akihiro Yachie; Hidetoshi Seki; Shoichi Koizumi
Journal:  Kidney Int       Date:  2003-10       Impact factor: 10.612

10.  Transgenic sickle mice have vascular inflammation.

Authors:  John D Belcher; Christopher J Bryant; Julia Nguyen; Paul R Bowlin; Miroslaw C Kielbik; John C Bischof; Robert P Hebbel; Gregory M Vercellotti
Journal:  Blood       Date:  2003-01-23       Impact factor: 22.113

View more
  105 in total

1.  Targeting βCys93 in hemoglobin S with an antisickling agent possessing dual allosteric and antioxidant effects.

Authors:  Tigist Kassa; M B Strader; Akito Nakagawa; Warren M Zapol; Abdu I Alayash
Journal:  Metallomics       Date:  2017-09-20       Impact factor: 4.526

Review 2.  Neutrophils, platelets, and inflammatory pathways at the nexus of sickle cell disease pathophysiology.

Authors:  Dachuan Zhang; Chunliang Xu; Deepa Manwani; Paul S Frenette
Journal:  Blood       Date:  2016-01-12       Impact factor: 22.113

3.  Macrophage metabolic adaptation to heme detoxification involves CO-dependent activation of the pentose phosphate pathway.

Authors:  Gael F P Bories; Scott Yeudall; Vlad Serbulea; Todd E Fox; Brant E Isakson; Norbert Leitinger
Journal:  Blood       Date:  2020-09-24       Impact factor: 22.113

4.  Targeting Mac-1-mediated leukocyte-RBC interactions uncouples the benefits for acute vaso-occlusion and chronic organ damage.

Authors:  Grace Chen; Jungshan Chang; Dachuan Zhang; Sandra Pinho; Jung-Eun Jang; Paul S Frenette
Journal:  Exp Hematol       Date:  2016-07-05       Impact factor: 3.084

5.  Control of Oxidative Stress and Inflammation in Sickle Cell Disease with the Nrf2 Activator Dimethyl Fumarate.

Authors:  John D Belcher; Chunsheng Chen; Julia Nguyen; Ping Zhang; Fuad Abdulla; Phong Nguyen; Trevor Killeen; Pauline Xu; Gerry O'Sullivan; Karl A Nath; Gregory M Vercellotti
Journal:  Antioxid Redox Signal       Date:  2016-03-30       Impact factor: 8.401

Review 6.  New insights into sickle cell disease: mechanisms and investigational therapies.

Authors:  Gregory J Kato
Journal:  Curr Opin Hematol       Date:  2016-05       Impact factor: 3.284

Review 7.  Influence of red blood cell-derived microparticles upon vasoregulation.

Authors:  Ahmed S Said; Allan Doctor
Journal:  Blood Transfus       Date:  2017-05-15       Impact factor: 3.443

Review 8.  Extracellular vesicles in coronary artery disease.

Authors:  Chantal M Boulanger; Xavier Loyer; Pierre-Emmanuel Rautou; Nicolas Amabile
Journal:  Nat Rev Cardiol       Date:  2017-02-02       Impact factor: 32.419

Review 9.  Pathophysiology of Sickle Cell Disease.

Authors:  Prithu Sundd; Mark T Gladwin; Enrico M Novelli
Journal:  Annu Rev Pathol       Date:  2018-10-17       Impact factor: 23.472

10.  Red Blood Cell Adhesion to Heme-Activated Endothelial Cells Reflects Clinical Phenotype in Sickle Cell Disease.

Authors:  Erdem Kucukal; Anton Ilich; Nigel S Key; Jane A Little; Umut A Gurkan
Journal:  Am J Hematol       Date:  2018-06-15       Impact factor: 10.047

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.